Norwich-Eaton
Executive Summary
Receives cash payment of $ 3.45 mil. from Bolar to settle its May 8 suit seeking damages for the generic firm's fraudulent marketing of a version of Norwich-Eaton's Macrodantin (nitrofurantoin). The complaint sought treble damages. Bolar's generic version generated sales of about $ 13 mil., according to the company's statements when it withdrew the ANDA for the product in 1989. So far this year, Bolar has paid out $ 56 mil. to settle lawsuits and still faces litigation from Warner-Lambert, Barr Labs and an SEC investigation. . . .